Cargando…
Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
The present study aimed to assess whether the methylation status of the protocadherin 17 gene (PCDH17) in triple-negative breast cancer (TNBC) tissues was associated with the efficacy of neoadjuvant chemotherapy (NAC). The present study included 280 patients diagnosed with TNBC using core needle bio...
Autores principales: | Kong, De-Di, Fu, Rong-Zhan, Li, Liang, Wang, WEI, Wang, Shi-Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377171/ https://www.ncbi.nlm.nih.gov/pubmed/32724406 http://dx.doi.org/10.3892/ol.2020.11737 |
Ejemplares similares
-
Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma
por: Lin, Ying-Li, et al.
Publicado: (2017) -
Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022) -
PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer
por: Elsharkawi, Sherif Mohamed, et al.
Publicado: (2023) -
High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023) -
Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)